Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

lutetium Lu 177-DOTA-ABM-5G

A radioconjugate composed of 5G, an agent targeting an as of yet undisclosed target, conjugated, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) and an albumin binding moiety (ABM), to the radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration of lutetium Lu 177-DOTA-ABM-5G, the 5G moiety targets and binds to a specific target on tumor cells. Upon binding, lutetium Lu 177 delivers a cytotoxic dose of beta radiation to the tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[177Lu]-DOTA-ABM-5G
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search